Yeah, well, the market knows the product is great, and the company has proven that it's good at proving it's great, BUT the market has had enough of hearing that now. Our only hope (as shareholders and for cancer-sufferers) is for the management to start doing deals.
Is it a case that management are just no good at the sales part of business? Or is it a case of Big Pharma not wanting to rush into a deal, because they are already making loads of money from what anti-cancer treatments they already have on the market that keeps the perpetual cancer-treatment wheel turning. Could it be that Cavatak is too effective and too safe for Big Pharma to want to commit.
Maybe Big Pharma are hoping that with time and further trials, there will be a hiccup. Who knows?
If the market doesn't know, it won't bother sticking around. We are certainly witnessing that now. No "Letter to the Shareholders" is going to bring in new blood... it's probably only going to fall on the deaf ears of the already converted or piss some of the tired bulls off for good!
I don't intend selling now, so probably best to take VLA off my "watchlist" and look at it in a year's time and then again in two. C'Est la Vie
VLA Price at posting:
60.0¢ Sentiment: Hold Disclosure: Held
